Skip to main content
H

Haemetrics

Haemetrics is developing a point-of-care diagnostic platform that quantitatively measures female reproductive health hormones from blood samples, providing results within 30 minutes. This technology enables healthcare providers to make timely, informed decisions regarding fertility and reproductive health, addressing the need for accessible and rapid diagnostic solutions in clinical settings.

Singapore, SingaporeFounded 2022300+ followers
Updated 4 months ago

Funding

$160K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current methods for assessing female reproductive health hormones often involve lab-based analysis, leading to delays in obtaining results and potentially hindering timely clinical decision-making. The reliance on centralized labs can also create accessibility barriers, particularly in point-of-care settings or for patients in remote locations.

Solution

Haemetrics is developing a point-of-care diagnostic platform designed for rapid, quantitative measurement of female reproductive health hormones directly from blood samples. The platform aims to deliver accurate results within 30 minutes, enabling healthcare providers to make informed decisions during the patient visit. By providing on-site hormone analysis, Haemetrics seeks to improve access to timely diagnostic information, streamline clinical workflows, and empower both doctors and patients in managing reproductive health. The device is intended for use in gynecology clinics, endocrinology practices, fertility centers, and diagnostic labs.

Target Audience

The primary target audience includes gynecologists, endocrinologists, fertility centers, and diagnostic labs involved in women's reproductive health.

Features

  • Tabletop device designed for on-site hormone analysis
  • Rapid results available within 30 minutes
  • Quantitative measurement of an array of female reproductive health-associated hormones
  • Intended for use with blood samples
  • Aims to provide economical and operational benefits for clinics by giving them complete control over tests
  • Complements existing offerings for diagnostic centers
This profile is AI-generated and may contain inaccuracies.